Applied Clinical Trials
Clinical grant expenditures represent a major portion of the budget for later phase clinical trials.
Clinical grant expenditures represent a major portion of the budget for later phase clinical trials. Although not the ultimate reason for picking a site or region to conduct clinical trials, the relative cost of conducting a clinical trial can play an important role in the decision.
TTC provides annual current global data on the relative costs of clinical grants around the world using data pulled from the GrantPlan® database. The sponsor company and CRO subscribers to this database conduct over 76 percent of all commercial clinical trials.
Mean Costs per Subject in Phase II-III Trials
This year, the data shows that the United States remains the most expensive country for clinical grants, often by a large margin, followed by the United Kingdom. Newer geographies such as Eastern Europe, Latin America, and Asia are distinctly less expensive for clinical research.
While less expensive, these areas show more rapid increases in clinical research spending than in North America or Europe. The United States and Western Europe (excluding the United Kingdom) have been averaging 3 percent to 4 percent annual increases. In contrast, clinical grants in the new geographies are increasing at rates over 14 percent.—TTC (for more information, please contact help@ttc-llc.com).
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.